Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

GAITHERSBURG, MD., JULY 30, 2026 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED THAT THE COMPANY PLANS TO RELEASE ITS SECOND QUARTER 2026 FINANCIAL RESULTS BEFORE THE OPEN OF THE U.S. FINANCIAL MARKETS ON THURSDAY, AUGUST 6, 2026.

NOVAVAX TO REPORT SECOND QUARTER 2026 FINANCIAL RESULTS ON AUGUST 6, 2026

RALEIGH, N.C., JUNE 24, 2026 (GLOBE NEWSWIRE) -- SHAH CAPITAL, THE LARGEST SHAREHOLDER OF NOVAVAX, TODAY COMMENTED ON YESTERDAY'S ANNOUNCED VOTING RESULTS FROM NOVAVAX'S JUNE 18TH 2026 ANNUAL MEETING OF STOCKHOLDERS.

SHAH CAPITAL RESPONDS TO SIGNIFICANT SHAREHOLDER DISSENT AT NOVAVAX AGM

GAITHERSBURG, MD., JUNE 1, 2026 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED IT WILL PARTICIPATE IN THE 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE.

NOVAVAX TO PARTICIPATE IN 2026 JEFFERIES GLOBAL HEALTHCARE CONFERENCE

GAITHERSBURG, MD., MAY 7, 2026 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE BOFA SECURITIES 2026 HEALTH CARE CONFERENCE.

NOVAVAX TO PARTICIPATE IN BOFA SECURITIES 2026 HEALTH CARE CONFERENCE

TOTAL REVENUE OF $140 MILLION IN THE FIRST QUARTER OF 2026 PFIZERAGREEMENTANNOUNCEDIN JANUARY FORNON-EXCLUSIVE LICENSE TOUTILIZEMATRIX-M  INTWOINFECTIOUSDISEASE AREAS IN APRIL, NOVAVAX SIGNED A NEW MTA WITH A TOP 10 LEADING PHARMACEUTICAL COMPANY AND LEADER IN ONCOLOGY TO EXPLORE MATRIX-M IN MULTIPLE ONCOLOGY AND INFECTIOUS DISEASE TARGETS IN APRIL, NOVAVAX EXPANDED AN EXISTING PARTNERSHIP WITH A NEW MTA, PROVIDING ACCESS TO MATRIX-M FOR EXPLORATION IN UP TO NINE ADDITIONAL IDENTIFIED INFECTIOUS DISEASES IN FEBRUARY, NOVAVAX EXPANDED AN EXISTING MTA WITH A MAJOR GLOBAL PHARMACEUTICAL COMPANY TO EXPLORE AN ADDITIONAL FIELD AND SIGNED A NEW MTA WITH AN ONCOLOGY COMPANY SANOFI ANNOUNCED POSITIVE RESULTS FROM THE PHASE 4 COMPARE STUDY, A HEAD-TO-HEAD STUDY COMPARING NUVAXOVID AND MODERNA'S MNEXSPIKE THAT REINFORCES NUVAXOVID'S WELL ESTABLISHED AND DIFFERENTIATED REACTOGENICITY PROFILE NOVAVAX'S C. DIFFICILE VACCINE CANDIDATE PRIORITIZED WITH POTENTIAL TO ENTER THE CLINIC AS EARLY AS 2027 REITERATES 2026 REVENUE FRAMEWORK AND COMBINED R&D AND SG&A EXPENSE GUIDANCE GAITHERSBURG, MD.

NOVAVAX REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

GAITHERSBURG, MD., APRIL 29, 2026 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED IT WILL REPORT ITS FIRST QUARTER 2026 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS AT 8:30 A.M.

NOVAVAX TO REPORT FIRST QUARTER 2026 FINANCIAL RESULTS ON MAY 6, 2026

ROBERT WALKER, MD, BRINGS MORE THAN 30 YEARS IN DRUG AND VACCINE DEVELOPMENT AND, MOST RECENTLY, SERVED AS NOVAVAX'S CHIEF MEDICAL OFFICER DR. WALKER WILL CONTINUE ADVANCING NOVAVAX'S R&D EFFORTS WITH A FOCUS ON DATA GENERATION TO FACILITATE PARTNERING DISCUSSIONS, MATRIX ADJUVANT INNOVATION AND ADVANCEMENT OF THE COMPANY PIPELINE GAITHERSBURG, MD., MARCH 30, 2026 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED THE APPOINTMENT OFDR. ROBERT WALKER, MD, ASEXECUTIVE VICE PRESIDENT AND HEAD OF RESEARCH & DEVELOPMENT (R&D).

NOVAVAX APPOINTS DR. ROBERT WALKER AS EXECUTIVE VICE PRESIDENT AND HEAD OF RESEARCH & DEVELOPMENT

GAITHERSBURG, MD., FEB. 26, 2026 /PRNEWSWIRE/ --NOVAVAX, INC. (NASDAQ: NVAX), TODAY ANNOUNCED THAT IT WILL PARTICIPATE IN THE FOLLOWING UPCOMING INVESTOR CONFERENCES: TD COWEN 46 TH ANNUAL HEALTH CARE CONFERENCE: FIRESIDE CHAT DATE: TUESDAY, MARCH 3, 2026 TIME: 2:30 P.M.

NOVAVAX TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

PFIZER AGREEMENT ANNOUNCED IN JANUARY 2026 FOR NON-EXCLUSIVE LICENSE TO UTILIZE MATRIX-M IN TWO INFECTIOUS DISEASE AREAS MULTIPLE MATERIAL TRANSFER AGREEMENTS SIGNED IN 2025 AND Q1 2026 WITH PHARMACEUTICAL COMPANIES, INCLUDING MAJOR GLOBAL PHARMACEUTICAL COMPANIES EXPLORING THE UTILITY OF MATRIX-M FOR THEIR VACCINE PORTFOLIOS SUCCESSFUL EXECUTION OF SANOFI PARTNERSHIP WITH $225 MILLION IN MILESTONES EARNED IN FULL YEAR 2025 TOTAL REVENUE OF $147 MILLION IN THE FOURTH QUARTER OF 2025 AND $1.1 BILLION FOR THE FULL YEAR 2025 CONTINUED ADVANCEMENT OF EARLY-STAGE PIPELINE WITH THE INTENTION TO ENTER THE CLINIC AS EARLY AS 2027 YEAR END 2025 CASH OF $751 MILLION NOVAVAX EXCEEDED ITS FULL YEAR 2025 R&D AND SG&A EXPENSE REDUCTION GOALS AND IS IMPROVING FUTURE TARGETS GAITHERSBURG, MD., FEB. 26, 2026 /PRNEWSWIRE/ -- NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED ITS FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2025.

NOVAVAX REPORTS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS

GAITHERSBURG, MD., FEB. 19, 2026 /PRNEWSWIRE/ --NOVAVAX, INC. (NASDAQ: NVAX) TODAY ANNOUNCED IT WILL REPORT ITS FOURTH QUARTER AND FULL YEAR 2025 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS AT 8:30 A.M.

Novavax, Inc.

NVAX

Price

Financial Reports

No items found.

Press Releases

Novavax, Inc.

NVAX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NVAX